throbber
Pharmacodynamic-guided, modified continuous reassessment method (mCRM)-based, do...
`
`Page 1 of 1
`
`Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
`Vol 24, No 18S (June 20 Supplement), 2006: 3020
`© 2006 American Society of Clinical Oncology
`
`Abstract
`
`Pharmacodynamic-guided, modified continuous reassessment
`method (mCRM)-based, dose finding study of rapamycin in
`adult patients with solid tumors
`
`A. Jimeno, P. Kulesza, G. Cusatis, A. Howard, Y. Khan, W. Messersmith, D. Laheru, E.
`Garrett-Mayer, S. D. Baker and M. Hidalgo
`
`Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
`
`3020
`
`Background: Pharmacodynamic (PD) studies, using either surrogate or tumor tissues, are
`
`frequently incorporated in Phase I trials. However, it has been less common to base dose
`
`selection, the primary endpoint in Phase I trials, in PD effects. We conducted a PD-based
`
`dose selection study with rapamycin (Rap). Methods: We used the modified continuous
`
`reassessment method (mCRM), a computer-based dose escalation algorithm, and adapted
`
`the logit function from its classic toxicity-based input data to a PD-based input. We coupled
`
`this design to a Phase I trial of Rap with 2 parts: a dose estimation phase where PD
`
`endpoints are measured in normal tissues and a confirmation phase where tumor tissue is
`
`assessed. Patients (pts) had solid tumors refractory to standard therapy. Rap was given
`
`starting at 2 mg/day continuously in 3-pt cohorts. The PD endpoint was pP70S6K in skin
`
`and tumor. Biopsies were done on days 0 and 28 of cycle 1, and a PD effect was defined
`
`as
`
` 80% inhibition from baseline. The first 2 dose levels (2 and 3 mgs) were evaluated
`
`before implementing the mCRM. The data was then fed to the computer that based on the
`
`PD effect calculated the next dose level. The mCRM was set so escalation continued until
`
`a dose level elicited a PD effect and the mCRM assigned the same dose to 8 consecutive
`
`pts, at which point the effect of that dose will be confirmed in tumor biopsies. Other
`
`correlates were PET-CT and pharmacokinetics. Results: Ten pts were enrolled at doses of
`
`2 mg (n = 4), 3 mg (n = 3) and 6 mg (n = 3). Toxicity was anemia (4 G1, 1 G2), leucopenia
`
`(1 G1, 2 G2), low ANC (2 G2), hyperglycemia (2 G1, 1 G2), hyperlipidemia (4 G1), and
`
`mucositis (1 G1, 1 G2). PD responses were seen in 2 and 1 pt at 2 and 3 mg dose levels.
`
`Input of data to the mCRM selected a dose of 6 mg for the third cohort, where PD effect
`
`was seen in 1 pt, and thus a fourth dose around 9 mg will be tested. No responses by
`
`RECIST occurred, but 2 pts had a response by PET. The PK was consistent with prior data
`
`(t1/2 24.6 ± 10.2 h, CL 31.4 ± 12.0 L/h, vol of distribution 235 ± 65 L), and exposure
`
`increased with dose. Steady-state concentration were in the 5–20 nM range. Conclusions:
`
`mCRM-based dose escalation based on real-time PD assessment is feasible and permits
`
`the exploitation of PD effects for dose selection in a rational manner.
`
`No significant financial relationships to disclose.
`
`Abstract presentation from the 2006 ASCO Annual Meeting
`
`Prescribing Information, including
`
`patients with severe hepatic impairment. Concomitant use of
`VOTRIENT and simvastatin increases the risk of ALT
`elevations and should be undertaken with caution
`Interactions
`during treatment,
`reduce, or discontinue dosing as recommended.
`
`Prescribing Information, including
`
`patients with severe hepatic impairment. Concomitant use of
`VOTRIENT and simvastatin increases the risk of ALT
`elevations and should be undertaken with caution
`Interactions
`during treatment,
`reduce, or discontinue dosing as recommended.
`
`http://meeting.ascopubs.org/cgi/content/short/24/18_suppl/3020
`
`ARGENTUM
`Exhibit 1064
`
`7/20/2016
`
`000001
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket